Steven Hyman directs the Stanley Center for Psychiatric Research of the Broad Institute of Harvard and MIT.

The Stanley Center focuses on psychiatric disorders, neurodevelopmental conditions, and neurodegenerative disorders including schizophrenia, bipolar disorder, autism spectrum disorders, ADHD, and Alzheimer’s. In addition to being the Director of the Stanley Center, Steve is Principal Investigator of the Schizophrenia Spectrum Biomarkers consortium (SSBC), a fluid biomarkers study with multiple collection sites across the US and collaborations with industry.

Biosketch

Steven E. Hyman, M.D., is a Harvard University Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology and a Core Institute Member of the Broad Institute of Harvard and MIT, where he directs the Stanley Center for Psychiatric Research. The Stanley Center engages in large-scale, globally conducted studies of neuropsychiatric genetics, stem cell biology, neurobiology, and technology development in support of translational efforts focused on reducing the global burden of psychiatric disorders.

From 2001 to 2011, Hyman served as provost (chief academic officer) of Harvard University, where he had a special focus on developing and supporting collaborative, interdisciplinary, and cross institutional efforts in the sciences, arts, and humanities. From 1996 to 2001, he served as director of the U.S. National Institute of Mental Health (NIMH), where he invested in neuroscience and emerging genomic technologies and initiated a series of large clinical effectiveness trials to inform practice.

He has served as editor of the Annual Review of Neuroscience (2002-2016), founding president of the International Neuroethics Society (2008-2013), president of the Society for Neuroscience (2015), and president of the American College of Neuropsychopharmacology (2018). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a distinguished life fellow of the American Psychiatric Association, and a member of the National Academy of Medicine (NAM). At the National Academies of Sciences, Engineering, and Medicine he has served on the NAM Council (2012-2018) and the governing board of the National Research Council (2016-2019), and chaired the National Academies’ Forum on Neuroscience and Nervous System Disorders (2012-2018), which brings together industry, government, foundations, patient groups, and academia. He is currently a member of the Committee on Science, Technology, and the Law (CSTL). He chairs the boards of directors of the Charles A. Dana Foundation (NY) and the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland), and is a director of Annual Reviews Inc (Palo Alto), a nonprofit scientific publisher. In the private sector he is a director of Voyager Therapeutics, Cyclerion Therapeutics, and Vesalius Therapeutics. He serves on the scientific advisory boards of Janssen Research and Development and F-Prime Capital. In 2016, he was awarded the Rhoda and Bernard Sarnat International Prize in Mental Health by the National Academy of Medicine.

Hyman received his B.A., summa cum laude, from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow studying history and philosophy of science, and an M.D., cum laude, from Harvard Medical School.